ARS Pharmaceuticals, Inc. (SPRY)

Market Cap	1.41B
Revenue (ttm)	500,000
Net Income (ttm)	-44.84M
Shares Out	96.94M
EPS (ttm)	-0.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,212,031
Open	14.21
Previous Close	14.05
Day's Range	14.21 - 15.22
52-Week Range	3.35 - 16.50
Beta	n/a
Analysts	Strong Buy
Price Target	24.00 (+65.4%)
Earnings Date	Nov 7, 2024

About SPRY

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRY
• Website: https://ars-pharma.com

Financial Performance

In 2023, ARS Pharmaceuticals's revenue was $30,000, a decrease of -97.72% compared to the previous year's $1.32 million. Losses were -$54.37 million, 56.8% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for SPRY stock is "Strong Buy." The 12-month stock price forecast is $24.0, which is an increase of 65.40% from the latest price.

Price Target

$24.0

(65.40% upside)

Analyst Consensus: Strong Buy